The INTERVAL trial was a randomised trial assessing how often blood donors can safely give whole blood, in which participants also consented to be part of a bio-resource enabling a broad range of health-related research.

About the Partnership

In addition to questions that can be answered by the randomised trial, we have also created a bioresource of the 50,000 trial participants to address other epidemiological questions, particularly those relating to genetics.

In all participants, we have:

  • collated basic lifestyle and self-reported health nformation using a web-based questionnaire;
  • assayed a genome-wide genotyping array containing >800,000 genetic variants;imputed from this array backbone to >80 million variants;
  • used a Sysmex haematology analyser to assay >50 blood cell parameters;assessed ~230 metabolites using a NMR platform covering lipoproteins, lipids and low molecular weight metabolites.

In subsets of participants, we have:

  • conducted high-depth (50x) whole exome sequencing;conducted low-pass (15x) whole genome sequencing;measured thousands of soluble proteins using a novel aptamer-based assay approach;
  • assayed >1000 metabolites using a mass-spectrometry platform;
  • assayed >400 lipid species using a bespoke mass-spectrometry platform;
  • measured candidate biomarkers of relevance to blood donation (eg, iron-related markers);
  • assessed cognitive function using a validated four-domain online testing platform.

Sanger Institute People

Sanger Team Partners

Related Programmes, Associate Research Programmes and Facilities

Related Collaborations